Lilly's experimental Alzheimer's therapy, donanemab, still has a “transformational growth opportunity,” despite Biogen's embattled rollout of Aduhelm, says J.P. Morgan Christ Schott.
It's been about four months since Biogen, Inc. (NASDAQ: BIIB) received approval for its controversial Alzheimer's treatment Aduhelm. The initial broad approval was later narrowed by the FDA. The "Aduhelm opportunity" for the biopharma is underappreciated, an analyst said Thursday. The Biogen Analyst: Needham's Ami Fadia initiated coverage of Biogen with a Buy rating and $400 price target. The Biogen Takeaways: Aduhelm sales may take time to ramp up and may miss consensus estimates in the near te
Biogen stock jumped Thursday on a fresh buy rating even as the controversy surrounding Alzheimer's drug Aduhelm deepened.